{"commentary":{"count":19,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"x_thread":6,"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03924856\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"KEYNOTE-866","nct_id":"NCT03924856","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-866-nct03924856. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"KEYNOTE-866","arms":[{"description":"Participants received 4 preoperative cycles of pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative pembrolizumab.","label":"Pembrolizumab + Gemcitabine + Cisplatin + Surgery","type":"EXPERIMENTAL"},{"description":"Participants received 4 preoperative cycles of placebo to pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative placebo to pembrolizumab.","label":"Placebo + Gemcitabine + Cisplatin + Surgery","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-05-18","type":"ACTUAL"},"conditions":["Bladder Cancer"],"enrollment":{"count":907,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])","type":"PROCEDURE"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-10-08","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-01-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-Free Survival (EFS)","timeFrame":"Up to approximately 60 months"}],"references":[{"citation":"Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19.","pmid":"34008425","type":"DERIVED"}],"start_date":{"date":"2019-06-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)","url":"https://clinicaltrials.gov/study/NCT03924856"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-866-nct03924856"}